Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a U.S.-based biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases. Its portfolio includes approved therapies for cystic fibrosis and newer medicines and product candidates in areas such as pain, sickle cell disease, beta thalassemia, type 1 diabetes, and kidney and immune-mediated diseases.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSmall-molecule therapies that treat the underlying cause of cystic fibrosis.
Non-opioid treatment for moderate-to-severe acute pain.
Ex vivo gene-edited therapy for severe blood disorders and related commercialization support.
Additional approved medicines and legacy product revenues outside the core CF franchise.
Upfront, milestone, and royalty-related revenue from collaborations and licensing.
Products
Reported · share of revenue- TRIKAFTAKAFTRIO85.5 %
- ALYFTREK6.9 %
- Manufactured Product Other6.8 %
- JOURNAVX0.5 %
- Collaborativeand Royalty0.3 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Vertex sells primarily to specialty pharmacies, specialty distributors, and major U.S. wholesalers, which then dispense through patients, health care providers, hospitals, and treatment centers. Outside the U.S., it relies mainly on distributor arrangements and direct sales in some markets, including authorized treatment centers for CASGEVY. Government agencies and public payors are important because reimbursement and coverage determine access in many of the company’s therapeutic areas.
Buy Vertex medicines in bulk and resell them into the U.S. specialty channel for chronic treatment use.
Purchase selected products for downstream distribution to pharmacies and care settings.
Buy products for resale in ex-U.S. markets, especially for CF medicines and other specialty therapies.
Receive CASGEVY and other therapies used in controlled treatment settings.
Support purchase eligibility, reimbursement, and patient access across markets.
Strategy
Vertex’s strategy centers on extending its cystic fibrosis franchise while building additional medicines in adjacent specialty-disease markets. It also uses acquisitions, licensing, and collaborations to add programs such as povetacicept, zimislecel, and gene-editing partnerships, while expanding manufacturing and commercialization capabilities to support launch execution.
CF remains the core commercial base and funds broader pipeline investment.
New approvals diversify revenue beyond CF and broaden the addressable market.
Local partners can accelerate development, approvals, and commercialization in Asia.
Specialty medicines and cell therapies require dependable third-party and internal capacity.
Geography
Vertex is headquartered in the United States and sells products in both the U.S. and international markets. The U.S. is the largest commercial market, while ex-U.S. sales are supported by distributors, pharmacies, hospitals, clinics, and government-linked customers; the company also has licensing and commercialization arrangements in parts of Asia for povetacicept. Geography matters because reimbursement, regulatory approval, and supply-chain execution differ by market and can affect access and commercialization timing.
Risks
Vertex depends heavily on a concentrated cystic fibrosis franchise, so any slowdown in that portfolio would affect the business disproportionately. Its pipeline, manufacturing, and commercialization model also creates execution risk because clinical development, regulatory approval, reimbursement, and third-party supply chains can all delay or limit product adoption.
- Dependence on cystic fibrosis medicinesImpact: CriticalLikelihood: Medium
Substantially all product revenue has historically come from CF therapies, so any erosion would be material.
Exposure: TRIKAFTA/KAFTRIO and related CF products
- Clinical development and regulatory failureImpact: HighLikelihood: High
Pipeline assets may not prove safe, effective, or approvable in late-stage trials.
Exposure - Supply-chain and manufacturing disruptionImpact: HighLikelihood: Medium
The company relies on third-party CROs, CMOs, and logistics providers for critical operations.
Exposure: Commercial products and clinical supply
- Pricing and reimbursement pressureImpact: HighLikelihood: Medium
Access depends on payer coverage, formulary placement, and government reimbursement decisions.
Exposure: U.S. and international specialty markets
- Geopolitical and sourcing riskImpact: MediumLikelihood: Medium
The company depends on China-based suppliers for portions of its supply chain.
Exposure: Global manufacturing inputs
Accounting
Judgemental itemsSpecialty pharmacy, distributor, and payor arrangements require estimates for rebates, chargebacks, and returns.
Impact: Affects reported product revenue and quarterly comparability
Deals such as Alpine create acquired intangibles that must be valued and monitored for impairment.
Impact: Can materially affect balance sheet and future expense recognition
Inventory built ahead of launches may need write-downs if demand, approval timing, or shelf life changes.
Impact: Affects cost of sales and gross profit timing
Collaborations and licenses can create contingent future payments tied to development or sales outcomes.
Impact: Affects future cash commitments and expense recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
Crispr Therapeutics AG
CRSP · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases.
Veraxa Biotech AG - Post de-SPAC
VRXAW · Pharmaceutical Preparations
Veraxa Biotech AG is a Switzerland-based biotechnology company focused on discovering and developing next-generation antibody-based cancer therapeutics.
PTC Therapeutics, Inc
PTCT · Pharmaceutical Preparations
PTC Therapeutics is a U.S.-based global biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders.
Veracyte, Inc
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
ZyVersa Therapeutics, Inc.
ZVSA · Pharmaceutical Preparations
Jazz Pharmaceuticals plc
JAZZ · Pharmaceutical Preparations
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on medicines for serious diseases, with a portfolio centered on neuroscience and oncology.
Last updated: 24/09/2026